Diabetes Clinical Trials in Brownsville
View 30 new treatments for Diabetes in Brownsville, TX. Every day, Power helps hundreds of Diabetes patients connect with leading medical research.Filter Results
Condition
All
How old are you?
Trial Phase
All
Trial Status
All
ILUVIEN® Implant for Diabetic Macular Edema
Alimera Sciences Clinic, McAllen + 1 more
This is a randomized, masked, active-controlled, parallel-group, multi-center study that will assess the efficacy of ILUVIEN as a baseline therapy in the treatment of Center Involving DME (CI-DME). The study will enroll patients who are either treatment naïve or have not received any DME treatments for the preceding 12 months as documented in medical records. Patients who received DME treatment \>12 months before screening, must not have received \>4 intravitreal injections. The study will compare 2 treatment regimens: ILUVIEN intravitreal implant (0.19 mg) followed by supplemental aflibercept as needed per protocol criteria (2 mg/0.05 mL), compared to intravitreal aflibercept loading dose (2 mg administered by intravitreal injection every 4 weeks for 5 consecutive doses) followed by supplemental aflibercept as needed per protocol criteria (2 mg/0.05 mL).Show More
Waitlist
No Placebo Trial
Phase 4
Est. 3 - 12 Weeks
Samer Kaba, MD
Study Chair
Faricimab for Diabetic Macular Edema
Research Clinic, McAllen + 1 more
This study will assess a pragmatic, treat and extend regimen of faricimab against the standard of a fixed dosing regimen.
Recruiting
No Placebo Trial
Phase 4
Est. 5 - 8 Weeks
Dr. Varun Chaudhary, MD, FRCS(C)
Principal Investigator
Aflibercept for Diabetic Retinopathy
Research Clinic, Harlingen + 1 more
The VOYAGE trial will assess diabetic retinopathy severity scale (DRSS) levels, through 112 weeks, while being managed with aflibercept as needed, among subjects who completed the 2-year PANORAMA trial (VGFTe-OD-1411) and were treated in a clinical setting prior to joining the VOYAGE study.Show More
Waitlist
No Placebo Trial
Phase 4
Est. 3 - 6 Weeks
Unregistered Study Lead
Research Team
Semaglutide for Prediabetes
Research Clinic, Brownsville + 1 more
This trial uses a hormone to study its effects on blood sugar, weight, heart health, and kidney function in Mexican-Americans with prediabetes. The goal is to understand how genetic differences affect individual responses to the hormone and to create personalized treatments for diabetes and related conditions. The hormone has been studied for many years, showing benefits in blood sugar control, weight loss, and heart health.Show More
Recruiting
No Placebo Trial
Phase 4
Est. 3 - 12 Weeks
Absalon D Gutierrez, MD
Principal Investigator
Retatrutide vs Semaglutide for Type 2 Diabetes
Eli Lilly Clinic, Weslaco + 1 more
The purpose of this study is to investigate the efficacy and safety of retatrutide compared with semaglutide in participants with Type 2 Diabetes and inadequate glycemic control with metformin with or without sodium-glucose cotransporter-2 inhibitor (SGLT2i). The study will last about 26 months and may include up to 24 visits.Show More
Recruiting
No Placebo Trial
Phase 3
Est. 5 - 8 Weeks
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Study Director
Retatrutide for Type 2 Diabetes
Eli Lilly Clinic, Weslaco + 1 more
The purpose of this study is to investigate the efficacy and safety of retatrutide compared with placebo in participants with Type 2 Diabetes and renal impairment, with inadequate glycemic control on basal insulin alone or a combination of basal insulin with or without metformin and/or sodium-glucose cotransporter-2 (SGLT2) inhibitor. The study will last about 14 months and may include up to 22 visits.Show More
Recruiting
Phase 3
Est. 6 - 12 Weeks
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Study Director
CagriSema for Type 2 Diabetes
Novo Nordisk Clinic, Brownsville + 2 more
This study will look at how much CagriSema helps participants with type 2 diabetes lower their blood sugar and body weight. CagriSema is a new investigational medicine. Doctors may not yet prescribe CagriSema. CagriSema will be compared to a "dummy" medicine (also called "placebo") that has no effect on the body. Participants will get either CagriSema or "dummy" medicine. Which treatment participants get is decided by chance. For each participant, the study will last for about one year.Show More
Recruiting
Phase 3
Est. 4 - 6 Weeks
Clinical Transparency (dept. 2834)
Study Director
Orforglipron for Type 2 Diabetes and Obesity
Eli Lilly Clinic, McAllen + 2 more
This trial is testing a new diabetes medication called orforglipron to see if it is safer and more effective than insulin in people with type 2 diabetes who are overweight or obese and at higher risk for heart problems. The study will last several years and involve multiple visits.Show More
Recruiting
No Placebo Trial
Phase 3
Est. 3 - 12 Weeks
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Study Director
Orforglipron vs Semaglutide for Type 2 Diabetes
Eli Lilly Clinic, Weslaco + 1 more
The main purpose of this study is to assess efficacy and safety of orforglipron compared with oral semaglutide in participants with Type 2 diabetes and inadequate glycemic control with metformin.The study will last around 61 weeks.Show More
Recruiting
No Placebo Trial
Phase 3
Est. 6 - 12 Weeks
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Study Director
Retatrutide for Type 2 Diabetes
Eli Lilly Clinic, Weslaco + 1 more
The purpose of this study is to investigate the efficacy and safety of retatrutide compared with placebo in participants with Type 2 Diabetes and inadequate glycemic control. The study will last about 11 months and may include up to 11 visits.Show More
Recruiting
Phase 3
Est. 5 - 8 Weeks
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Study Director
Page 1 of 3
Frequently Asked Questions
Explore related conditions